CINE PAR : Dépôt du projet de note d'information modifié

Ciné Par, agissant de concert avec le groupe familial Seydoux, lance une offre publique de retrait sur les actions Gaumont à 100€ par action, sur une durée de 10 jours de négociation (soumise à l’examen de l’AMF). Le prix représente une prime de 23,5% vs le cours de clôture du 13/10/2025 et des primes d’environ 24,6% à 27,3% vs les moyennes pondérées des volumes sur 60-180 jours. L’initiateur détient déjà 89,95% du capital et 94,42% des droits de vote ; en cas d’apports, le montant total à verser est estimé à 31,7M€.

Analysis

This is a governance/liquidity event more than a fundamental one. The relevant mechanism is not operating uplift but the collapse of discount-to-bid: once the AMF process clears, the remaining float should behave like a near-cash instrument, and any persistent spread will mostly reflect execution friction, not balance-sheet risk. The controlling family’s economics are asymmetric: they eliminate a nuisance public listing and preserve optionality over future capital allocation while bearing almost no incremental strategic risk.

The bigger second-order effect is on holders of other French family-controlled microcaps: this is a reminder that illiquidity can become a regulatory liability, not just a valuation discount. For the listed ecosystem, the supply of “unowned” shares shrinks and that can mechanically support the last leg into the offer, but it also leaves a residual-stub problem if a handful of investors refuse to tender. That stub is where pricing can get irrational in the final days: it may trade above the headline bid on squeeze dynamics or below it if investors overestimate deal risk.

Time horizon matters. Over days, the trade is spread capture; over 1-3 months, the main catalyst is AMF conformity and completion; over 6-18 months, the only real debate is whether the issuer remains listed with an even thinner free float or quietly becomes a private asset again. The consensus is likely underweighting how little upside remains once the bid is public and fully financed, but also overestimating the relevance of stated no-delisting intentions, which can change once the public float is negligible.

Key Decisions for Investors

• If GAM.PA still trades at a material discount to EUR 100 after AMF conformity, buy the cash arb; target convergence to the bid with a tight stop if the spread widens on any regulatory delay.
• Do not force a long in BNPQY/BNP Paribas on this headline; financing and presentation economics are immaterial versus group earnings, so it is not a clean catalyst trade.
• For any existing Gaumont holder, tender rather than gamble on the stub: if acceptance ends up light and the stock remains listed, residual liquidity risk will be the real downside.
• Watch for the AMF declaration of conformity and the independent expert’s wording; if either implies a price revision above EUR 100, cover any arb shorts immediately, but absent that, the risk/reward is skewed toward holding only until close.
• Treat a post-announcement rally above EUR 100 as a warning sign of deal uncertainty, not extra upside; that would be the level where the market is pricing either a sweeter bid or slippage in the timetable.